Core Points - Prestige Consumer Healthcare Inc. will release its fiscal 2026 second quarter and first half earnings on November 6, 2025, before market opening [1] - A conference call to discuss the earnings results will take place on the same day at 8:30 a.m. ET [1] Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes consumer healthcare products across the U.S., Canada, Australia, and other international markets [4] - The company's product portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [4]

Prestige Consumer Healthcare Conference Summary Company Overview - Prestige Consumer Healthcare Inc. (NYSE: PBH) is a consumer healthcare company focused on over-the-counter medicines, helping consumers care for themselves daily [2][3] Key Business Segments - The company has a diversified portfolio of brands, including: - Monistat (50%+ market share in vaginal antifungal treatment) - Summer's Eve (40%+ market share in feminine hygiene) - Dramamine (60% market share in motion sickness) [4][5][10] Financial Performance - Over the last five years, total revenue grew by approximately 3.5%, with organic revenue growth in the range of 2% to 3% [9] - Adjusted earnings increased by about 9% annually, exceeding the long-term target of 6% to 8% [9] - The company maintains best-in-class EBITDA margins in the low 30s, contributing to strong free cash flow generation [7][22] Growth Strategy - The growth strategy is built on three pillars: 1. Investing in brand building to achieve 2% to 3% organic growth [6] 2. Maintaining a strong financial profile with an asset-light model and high free cash flow [7] 3. Reinvesting free cash flow into capital allocation for further growth and potential acquisitions [8][22] E-commerce Growth - E-commerce sales have increased from less than 1% to over 16% of total sales in the last five years, driven by investments in content and marketing [15][16] - The company aims to be channel-agnostic, ensuring products are available across various platforms [40] Innovation and Brand Building - The company introduces 3 to 5 new products annually, focusing on incremental innovations rather than large-scale launches [17] - Recent innovations include expanding the Dramamine brand to include non-drowsy options and nausea relief products [11][12] - The introduction of a maintain subline for Monistat allows for broader usage beyond acute treatment [19] International Expansion - The international segment accounts for about 16% of sales, with expected growth rates exceeding 5% [20] - Key brands include Hydralyte, a leading rehydration product in Australia, with plans for geographic expansion [20][21] Capital Allocation Strategy - The company prioritizes: 1. Investing in current brands for organic growth 2. M&A opportunities to consolidate consumer healthcare brands 3. Strategic share repurchases to offset dilution [23][24] - The company has a long-term leverage target of less than 3 times, currently at 2.4x [22] Challenges and Future Outlook - The Clear Eyes brand faced supply chain challenges, leading to a shortfall in revenue. The company is acquiring a critical supplier to enhance production capacity [26][32] - The long-term outlook remains positive, with expectations for continued free cash flow generation and strategic capital allocation to enhance shareholder value [26][27] Conclusion - Prestige Consumer Healthcare is well-positioned for sustainable growth through a diversified brand portfolio, strong financial management, and a focus on innovation and market expansion [27]

Core Insights - Prestige Consumer Healthcare Inc. is focusing on growth in its eye care business despite operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma aims to resolve supply constraints and support long-term expansion in the eye care segment [2] - The company reported a 6.6% year-over-year revenue decline in Q1 2026 but showed momentum in other segments, including international OTC healthcare growth [3] Group 1: Company Strategy - Prestige Consumer Healthcare Inc. is taking strategic steps to secure growth in its eye care business amid operational challenges in 2025 [1] - The acquisition of Pillar5 Pharma is intended to address previous supply constraints and ensure reliable production for the Clear Eyes brand [2] Group 2: Financial Performance - The company experienced a 6.6% year-over-year revenue decline in Q1 2026 [3] - Despite the revenue decline, there was momentum in other business segments, including international OTC healthcare growth and improved gross margins [3] Group 3: Leadership Perspective - CEO Ron Lombardi emphasized that integrating Pillar5's capabilities strengthens the Clear Eyes franchise and enhances overall business resilience [3]

Company Overview - Prestige Consumer Healthcare focuses on niche categories where brands can compete successfully over the long term [2] - The company emphasizes the breadth and depth of its consumer connections through its product offerings [2] Product Impact - The company sells enough Clear Eyes and TheraTears to treat 12 billion irritated eye occasions annually [2] - It addresses 650 million sore and dry throat occasions each year [2] - The BC and Goody's powdered analgesic brands help treat approximately 17 million pain occasions weekly, including hangovers [2] - Monistat assists in treating about 8 million vaginal yeast infections annually [2]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook for this year exceeding $245 million [10][48] - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [12] Business Line Data and Key Metrics Changes - The largest category for the company is gastrointestinal (GI) health, followed by women's health, eye and ear care, skin care, and analgesics [4] - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][51] Market Data and Key Metrics Changes - The company's e-commerce sales have grown significantly, increasing from about 4% of total sales five years ago to approximately 16% at the end of the last fiscal year, with two-thirds of that coming from Amazon [25] - The international business, particularly in Australia, has been growing in the mid-teens on average over the last five years, exceeding long-term expectations [37] Company Strategy and Development Direction - The company focuses on niche categories where brands can compete successfully over the long term, emphasizing brand building and consumer insights [2][8] - The management plans to utilize free cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a strong balance sheet [41][42] Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting the Clear Eyes brand but expressed confidence in addressing these issues with new suppliers coming online [47][48] - The company maintains its free cash flow outlook despite adjustments to top-line expectations, indicating resilience in its business model [48] Other Important Information - The company has a strong financial profile characterized by low capital expenditures and a variable cost model, which supports consistent free cash flow generation [40] - The management highlighted the importance of consumer insights in driving product innovation and brand growth [53] Q&A Session Summary Question: What are the kind of valuations the company is seeing? - The company has not observed a meaningful shift in valuations for the brands it targets, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [59] Question: How does the company view the shift in retail channels? - Management noted that channel shifts are not new and emphasized the importance of adapting marketing strategies to support retail partners across various channels, including drugstores and e-commerce [61][62]

Financial Data and Key Metrics Changes - The company reported a free cash flow of approximately $242 million for the previous year, with an outlook of over $245 million for the current year, indicating a strong financial profile and consistent cash generation [9][48]. - The five-year compound annual growth rates (CAGRs) showed revenue growth of about 3.5%, organic growth of 2.5%, and earnings per share (EPS) growth of nearly 9% [11]. Business Line Data and Key Metrics Changes - The company operates in several categories, with gastrointestinal (GI) being the largest, followed by women's health, eye and ear care, skin care, and analgesics [4][5]. - The company has a diverse portfolio that allows it to manage fluctuations in illness levels effectively, with brands performing variably based on market conditions [6][10]. Market Data and Key Metrics Changes - The e-commerce segment has grown significantly, with online sales increasing from about 4% of total sales five years ago to approximately 16% by the end of the last fiscal year, with two-thirds of that attributed to Amazon [24][25]. - The international business, particularly in Australia, has been growing in the mid-teens, exceeding long-term expectations of mid to high single-digit growth [36]. Company Strategy and Development Direction - The company focuses on investing in niche categories where brands can compete effectively, emphasizing a brand-building playbook that includes understanding consumer insights and agile marketing strategies [2][12]. - The company aims to utilize its strong cash flow for mergers and acquisitions (M&A), share repurchases, and maintaining a low leverage ratio, with a preference for M&A as the primary use of cash [41][42]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged capacity constraints affecting certain brands but expressed confidence in addressing these issues through new supplier agreements and operational adjustments [46][48]. - The company maintains its free cash flow outlook despite adjustments to top-line revenue expectations, indicating resilience in its financial performance [48]. Other Important Information - The company has a disciplined approach to M&A, focusing on acquiring brands with leading positions in niche categories, and has significant acquisition capacity without returning to previous high leverage levels [44][45]. - The company has successfully launched several new products, including Dramamine advanced herbals for kids and Summer's Eve whole body deodorant, which have performed well in their respective markets [31][33]. Q&A Session Summary Question: What are the kind of valuations the company is seeing in the market? - The company has not observed a meaningful shift in valuations for the types of brands it seeks, emphasizing its competitive advantages over private equity in terms of cost of capital and operational sophistication [58][59]. Question: How does the company view the shift in retail channels from traditional drugstores to clubs and retailers? - The company has adapted to channel shifts by developing unique programs for each retail partner and remains committed to supporting brands in the drug channel while also leveraging opportunities in e-commerce and other retail formats [60][62].

Financial Performance & Strategy - FY25 revenues reached $1,137.8 million[69] - The company achieved a 5-year revenue CAGR of 34%[17,69] - Adjusted EPS 5-year CAGR was +88%[17] - Organic revenue 5-year CAGR was +24%[17,69] - Adjusted FY25 Free Cash Flow reached $243291 thousand[49,75] - Net leverage was significantly reduced to 24x[49] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[51] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[45] FY26 Outlook - Expected revenue for FY26 is projected to be between $1,100 to $1,115 million[59] - Projected FY26 Non-GAAP Free Cash Flow is $245 million[59,77]

Group 1 - Prestige Consumer Healthcare Inc. will present at the Barclays Global Consumer Staples Conference on September 4, 2025, at 12:45 p.m. ET [1] - Interested parties can access a live webcast of the event on the company's website under the "Investors" section [1] - A replay option will be available on the company's website for those unable to participate in the live webcast [1] Group 2 - Prestige Consumer Healthcare is a leading consumer healthcare products company with sales in the U.S., Canada, Australia, and other international markets [2] - The company's diverse portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [2]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11,200,000, representing a $13,000,000 improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261,400,000, with gross profit rising to $137,000,000, up from $126,000,000, resulting in a gross profit margin of 52.4% [19][20] - The group achieved a record number of rolling twelve-month cash actives at 295,800, marking a significant milestone [10] Business Line Data and Key Metrics Changes - In Australia, revenue reached $218,500,000, a 3% increase from the PCP, with gross profit also at a record of $114,500,000, up 2% [11] - The Australian business achieved a statutory segment EBITDA of $30,100,000, reflecting a 12% increase from the PCP [13] - In Canada, net win grew by 26% to $43,000,000, with sports betting net win at $17,000,000, up 11%, and iGaming net win at $26,000,000, increasing by 39% [16][17] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for FY 2025, despite PointsBet gaining market share [26][27] - The Canadian market showed strong growth momentum, with a significant increase in cash active clients by 30% to 58,004 [17][18] Company Strategy and Development Direction - PointsBet is focused on enhancing its mass market recreational segments in both Australia and Canada to create a more diversified and sustainable revenue base [10] - The company is actively encouraging reforms in the wagering industry regarding advertising, aiming for a sustainable framework that leverages digital and social media platforms [14][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, indicating challenges ahead but expressed hope for a return to growth based on recent positive trends [26][27] - The company anticipates continued market growth tailwinds in the regulated Canadian market, particularly with Alberta expected to go live [18] Other Important Information - PointsBet's board has recommended shareholders accept the MiXi Australia takeover offer, which provides a 50.6% cash premium over the share price prior to the announcement [4][6] - The company paid $115,300,000 in taxes and fees to Australian governments and sports bodies, representing 47.9% of its net win for the year [14] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators, indicating potential for future growth [26][27] Question: What are the next steps if MiXi exceeds 50.1% ownership? - If MiXi achieves over 50.1% before the offer closes, it will trigger a two-week extension for the offer [28][29]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11.2 million, a $13 million improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261.4 million, with gross profit rising to $137 million, up from $126 million, resulting in a gross profit margin of 52.4% [18][19] - The gross profit margin decreased by 0.4 percentage points compared to the PCP [19] Business Line Data and Key Metrics Changes - In Australia, revenue reached a record $218.5 million, up 3% from the PCP, with gross profit also at a record $114.5 million, up 2% [11] - The Australian gross win margin improved by 1.8 percentage points to 13.6%, while the net win margin increased by 1 percentage point to 10.4% [12] - In Canada, net win grew by 26% to $43 million, with sports betting net win at $17 million, up 11%, and iGaming net win at $26 million, up 39% [15][16] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for the year, despite PointsBet gaining market share [26] - The Canadian market showed strong turnover growth, maintaining PointsBet's net win market share [15] Company Strategy and Development Direction - PointsBet aims to diversify its revenue base by focusing on mass market recreational segments in both Australia and Canada [10] - The company is actively encouraging reforms in the wagering industry regarding advertising to leverage digital and social media platforms [14] Management Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, but there are signs of improvement in the last quarter [26] - The company expects continued market growth tailwinds in the regulated Canadian market [17] Other Important Information - PointsBet paid $115.3 million in taxes and fees to Australian governments and racing bodies, representing 47.9% of its net win for the year [14] - The company had $22.7 million in corporate cash and net assets of $6 million as of June 30, 2025 [21] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators [26] Question: What are the next steps if MiXi increases above 50.1%? - If MiXi goes through 50.1% before the offer closes, it would trigger a two-week extension for the offer [28][29]